In three different cancer cell lines (A549, H358 and H460) CBD dose dependently (1nM-3μM) increased ICAM-1 and TIMP-1 through TRPV1. In mice carrying human lung cancer xenografts, CBD increased ICAM-1 and TIMP-1 2.6-3.0-fold, inhibiting lung cancer cell invasion and metastasis (Ramer et al., 2012).

In cancer cell lines (A549 and H460) and human metastatic lung cancer cells CBD as well as THC promote ICAM-mediated Lymphokine-Activated Killer cell adhesion and cancer cell lysis (Haustein et al., 2014).

In cancer cell lines (A549 and H460) and human metastatic lung cancer cells CBD induced apoptosis via COX-2 and PPARγ. In A549-xenografted mice CBD caused tumor regression (Ramer et al., 2013).

Literature:

Haustein, M., Ramer, R., Linnebacher, M., Manda, K., & Hinz, B. (2014). cannabinoids increase Lung Cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochemical Pharmacology, 92(2), 312-325. https://doi.org/10.1016/j.bcp.2014.07.014

Ramer, R., Bublitz, K., Freimuth, N., Merkord, J., Rohde, H., Haustein, M., … Hinz, B. (2012). Cannabidiol inhibits Lung Cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 26(4), 1535-1548. https://doi.org/10.1096/fj.11-198184

Ramer, R., Heinemann, K., Merkord, J., Rohde, H., Salamon, A., Linnebacher, M., & Hinz, B. (2013). COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human Lung Cancer cells. Molecular cancer Therapeutics, 12(1), 69-82. https://doi.org/10.1158/1535-7163.MCT-12-0335